Benzinga··Vandana SinghGilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio
Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval